| Ol (lots) | Call Price | Strike Price | Put Price | Ol (lots) |
|---|---|---|---|---|
| 2500% | ₹764.2 -4.23% | 2,600 | ₹0.5 0% | 2500% |
| - | - | 2,800 | ₹3.15 -5.97% | 4,00033.33% |
| - | - | 2,900 | ₹3.7 -36.75% | 16,000137.03% |
| 5000% | ₹425.95 8.67% | 2,950 | ₹4.2 -48.46% | 6,750237.5% |
| 7500% | ₹252.85 0% | 3,000 | ₹7.65 -30.13% | 56,250251.56% |
| 500100% | ₹366.8 4.75% | 3,050 | ₹8 -49.2% | 13,75096.42% |
| 1,50020% | ₹321.35 17.45% | 3,100 | ₹11.95 -40.54% | 49,00092.15% |
| 75050% | ₹279 87.87% | 3,150 | ₹19.5 -32.4% | 8,75059.09% |
| 17,250-15.85% | ₹254.55 22.08% | 3,200 | ₹24.85 -33.64% | 50,00019.04% |
| 17,75022.41% | ₹215.6 26.71% | 3,250 | ₹33.3 -35.15% | 20,00014.28% |
| 54,000-15.29% | ₹175.3 23.93% | 3,300 | ₹48 -30.48% | 54,000-7.29% |
| 49,25071.30% | ₹144.95 26.59% | 3,350 | ₹63.25 -27.83% | 43,500109.63% |
| 1,45,000128.34% | ₹115.55 27.53% | 3,400 | ₹82.25 -25.9% | 85,000496.49% |
| 61,2501533.33% | ₹90.9 22.01% | 3,450 | - | - |
| 1,26,500208.53% | ₹70.3 30.18% | 3,500 | ₹135.9 -23.17% | 9,000300% |
| 40,500174.57% | ₹52.1 25.24% | 3,550 | - | - |
| 2,20,500666.95% | ₹39.3 26.97% | 3,600 | ₹258.05 -2.84% | 5000% |
| 28,5000% | ₹29.65 0% | 3,650 | - | - |
| 94,750362.19% | ₹22.65 40.24% | 3,700 | ₹361.85 0% | 5000% |
| 87,000954.54% | ₹13.05 47.45% | 3,800 | - | - |
The acquisition values JB Chemicals at ₹25,689 crore on a fully diluted basis, according to the company’s official announcement.
On the operating front, EBITDA for the quarter was reported at ₹964 Crore. It was 9.20% higher than ₹883 in Q4FY24.
Here are some of the stocks that may see significant price movement today: JK Cement, KEC International, Macrotech Developers, etc.
Empagliflozin is a new sodium-glucose co-transporter-2 (SGLT-2) inhibitor approved for glycemic management in individuals with type 2 diabetes.
The USFDA examined Torrent's manufacturing plant in Pithampur during the September quarter and issued a Form 483 with one observation.
The business reported a 13% growth in India revenues to ₹1,632 Crore, driven by outperformance in focus therapies.
When compared to the previous quarter, revenue growth was modest at 1.05%, while net profits experienced a slight decline of 0.88%.
In August, the CDSCO banned more than 156 fixed-dose combination medications from the Indian market.
Here are some of the stocks that may see significant price movement today: Nuvama Wealth, RITES, Torrent Pharmaceuticals, etc.
The company announced that its India business grew by 10% year on year in the June quarter, with sales rising to ₹1,635 Crore from ₹1,426 Crore in Q1 FY24.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
